Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Rhea-AI Summary

Shuttle Pharmaceuticals (Nasdaq: SHPH) will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. CEO Dr. Anatoly Dritschilo will present updates on the Phase 2 clinical trial of Ropidoxuridine for glioblastoma and the development of predictive biomarkers for prostate cancer by Shuttle Diagnostics, Inc. The webcast presentation will be at 11:00 am ET, with virtual one-on-one meetings available throughout the event. The webcast can be accessed via the conference homepage or directly. Shuttle Pharmaceuticals focuses on enhancing radiation therapy outcomes for cancer patients.

Positive

• Participation in the Lytham Partners Spring 2024 Investor Conference provides exposure and networking opportunities.
• CEO will present updates on Phase 2 clinical trial of Ropidoxuridine for glioblastoma, showing progress in clinical development.
• Development of predictive biomarkers for prostate cancer by Shuttle Diagnostics could lead to innovative cancer treatment approaches.
• Webcast presentation provides transparency and accessibility to investors.
• One-on-one meetings offer personalized engagement with potential investors.

Negative

• No specific financial or clinical trial results were disclosed.
• The focus on early-stage clinical development indicates potential long timelines before marketable products.
• Reliance on investor conferences may suggest a need for additional funding.
• information on current financial performance or revenue projections.

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Dr. Dritschilo’s presentation will include an update on the Company's progress toward clinical and scientific milestones of its Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure. Additionally, he will provide an update on the Company’s plans of its subsidiary, Shuttle Diagnostics, Inc., to develop predictive biomarkers for prostate cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.

Company Webcast

The webcasted presentation will take place at 11:00 am ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/shph/2100483. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.

About Shuttle Pharmaceuticals

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.

Shuttle Pharmaceuticals

Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com

Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com

FAQ

What will Shuttle Pharmaceuticals present at the Lytham Partners Spring 2024 Investor Conference?

CEO Dr. Anatoly Dritschilo will provide updates on the Phase 2 clinical trial of Ropidoxuridine for glioblastoma and the development of predictive biomarkers for prostate cancer.

When is Shuttle Pharmaceuticals' presentation at the Lytham Partners Spring 2024 Investor Conference?

The presentation will be webcasted at 11:00 am ET on Thursday, May 30, 2024.

How can investors access Shuttle Pharmaceuticals' webcast presentation?

The webcast can be accessed through the conference homepage or directly via a provided link.

Is Shuttle Pharmaceuticals conducting one-on-one meetings at the Lytham Partners Spring 2024 Investor Conference?

Yes, management will participate in virtual one-on-one meetings throughout the event.

What is the focus of Shuttle Pharmaceuticals' research?

Shuttle Pharmaceuticals focuses on improving radiation therapy outcomes for cancer patients by developing radiation sensitizers and predictive biomarkers.